Healthcare Equities

The companies that provide, support or coordinate medical goods and services. This sector spans a broad range of activities – including the development and manufacture of medical equipment, pharmaceuticals and other treatments. Activities range from research to manufacturing, administration, insurance and facilities management. Our Healthcare research includes healthcare services, healthcare information technology (IT), medical devices, biotechnology, biopharmaceuticals and specialty pharmaceuticals.

Nykode Therapeutics (NYKD)

Latest price

NOK2.54

▾ 0.30 (13.19)

As at 15/04/2025

Market capitalisation: NOK733m

View equity

QuickView

Healthcare

09.12.24

USD1.12

▾ 0.03 (2.76)

As at 15/04/2025

Market capitalisation: USD38m

View equity

OpGen (OPGN)

Latest price

—

— 0.00 (0.00)

As at 15/04/2025

Market capitalisation: —

View equity

Update

Healthcare

14.08.23

OpGen — Cash concerns dampen active Q2

Flash note

Healthcare

04.08.23

OpGen — FIND collaboration advances to development

Flash note

Healthcare

21.07.23

EUR2.79

▾ 0.01 (0.18)

As at 15/04/2025

Market capitalisation: EUR184m

View equity

Flash

Healthcare

15.04.25

Oryzon Genomics — First patient dosed in iadademstat + ICI SCLC trial

Update

Healthcare

04.03.25

Oryzon Genomics — All steady heading into 2025

edison tv

Healthcare

10.12.24

EUR5.75

▾ 0.19 (3.42)

As at 15/04/2025

Market capitalisation: EUR127m

View equity

Outlook

Healthcare

03.04.25

OSE Immunotherapeutics — Primed for value appreciation

edison tv

Healthcare

26.03.25

OSE Immunotherapeutics — Lusvertikimab and the future of IBD: KOL insights post-ECCO webinar

Flash

Healthcare

12.03.25

AUD0.01

— 0.00 (10.00)

As at 15/04/2025

Market capitalisation: GBP12m

View equity

Recce Pharmaceuticals (RCE)

Latest price

AUD0.29

▾ −0.01 (−1.72)

As at 15/04/2025

Market capitalisation: AUD68m

View equity

Team of Research Scientists Working On Computer, with Medical Equipment, Analyzing Blood and Genetic Material Samples with Special Machines in the Modern Laboratory.

Update

Healthcare

28.03.25

Recce Pharmaceuticals — Gearing up for an eventful year for R327G

Flash

Healthcare

20.02.25

Recce Pharmaceuticals — Positive R327G Phase II ABSSSI study results

Flash note

Healthcare

17.12.24

SEK6.55

▾ −0.12 (−1.80)

As at 15/04/2025

Market capitalisation: SEK738m

View equity

Non client QV

Healthcare

10.04.25

CHF13.56

— 0.00 (0.00)

As at 15/04/2025

Market capitalisation: CHF184m

View equity

Sareum Holdings (SAR)

Latest price

GBP0.19

▾ −1.50 (−7.32)

As at 15/04/2025

Market capitalisation: GBP24m

View equity

Spotlight — update

Healthcare

10.04.25

Sareum Holdings — Broader pipeline, bigger milestones

Spotlight — flash

Healthcare

14.03.25

Sareum Holdings — New fund-raise and licence signal active 2025

edison tv

Healthcare

25.11.24

USD6.04

▾ −0.11 (−1.79)

As at 15/04/2025

Market capitalisation: USD432m

View equity

Flash

Healthcare

10.04.25

SIGA Technologies — Dividends bring cheer amid market uncertainty

Update

Healthcare

19.03.25

SIGA Technologies — Entering a crucial period for business outlook

Update

Healthcare

18.11.24

SIGA Technologies — Strong order book moving into Q424

See more
content on

SIGA Technologies

Equities

Equities by Sector

Sectors

Thematics

Latest

Hybrid Air Vehicles – Redefining air travel and air freight

The humanoid revolution walking your way: How robots are stepping out of science fiction

From gold to gold miners: Extracting higher returns in the current bull run

Audiovisual

Latest

discoverIE Group – executive interview

Spotting the next big winners: UK small caps with Aberdeen’s Abby Glennie

Nabaltec – executive interview

About Edison

About Edison

Careers

Healthcare Equities

Nykode Therapeutics (NYKD)

NOK2.54

Nykode Therapeutics — Repositioned to streamline clinical progress

See morecontent on

Okyo Pharma (OKYO)

USD1.12

OpGen (OPGN)

—

OpGen — Cash concerns dampen active Q2

OpGen — FIND collaboration advances to development

OpGen — Feasibility milestone from FIND collaboration

See morecontent on

Oryzon Genomics (ORY)

EUR2.79

Oryzon Genomics — First patient dosed in iadademstat + ICI SCLC trial

Oryzon Genomics — All steady heading into 2025

Oryzon Genomics – executive interview

See morecontent on

OSE Immunotherapeutics (OSE)

EUR5.75

OSE Immunotherapeutics — Primed for value appreciation

OSE Immunotherapeutics — Lusvertikimab and the future of IBD: KOL insights post-ECCO webinar

OSE Immunotherapeutics — Tedopi shows promise in pancreatic cancer

See morecontent on

Percheron Therapeutics (PER)

AUD0.01

Recce Pharmaceuticals (RCE)

AUD0.29

Recce Pharmaceuticals — Gearing up for an eventful year for R327G

Recce Pharmaceuticals — Positive R327G Phase II ABSSSI study results

Recce Pharmaceuticals — BPOM clearance to start Phase III R327G study

See morecontent on

Saniona (SANION)

SEK6.55

Saniona — Broad pipeline to address neurological conditions

See morecontent on

Santhera Pharmaceuticals (SANN)

CHF13.56

Sareum Holdings (SAR)

GBP0.19

Sareum Holdings — Broader pipeline, bigger milestones

Sareum Holdings — New fund-raise and licence signal active 2025

Sareum Holdings – executive interview

See morecontent on

SIGA Technologies (SIGA)

USD6.04

SIGA Technologies — Dividends bring cheer amid market uncertainty

SIGA Technologies — Entering a crucial period for business outlook

SIGA Technologies — Strong order book moving into Q424

See morecontent on

Subscribe to Edison

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on